CY1112008T1 - Ανασυνδυασμενος αδενοϊος οροτυπου ad11 - Google Patents

Ανασυνδυασμενος αδενοϊος οροτυπου ad11

Info

Publication number
CY1112008T1
CY1112008T1 CY20111101074T CY111101074T CY1112008T1 CY 1112008 T1 CY1112008 T1 CY 1112008T1 CY 20111101074 T CY20111101074 T CY 20111101074T CY 111101074 T CY111101074 T CY 111101074T CY 1112008 T1 CY1112008 T1 CY 1112008T1
Authority
CY
Cyprus
Prior art keywords
serotypes
natural
proteins
capsid
tropism
Prior art date
Application number
CY20111101074T
Other languages
English (en)
Inventor
Ronald Vogels
Menzo Jans Emko Havenga
Abraham Bout
Original Assignee
Crucell Holland B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112008(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland B.V. filed Critical Crucell Holland B.V.
Publication of CY1112008T1 publication Critical patent/CY1112008T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Abstract

Οι ορότυποι διαφέρουν στο φυσικό τροπισμό αυτών. Οι ορότυποι 2, 4, 5 και 7 αδενοϊού έχουν όλοι μία φυσική θυγατρική σχέση προς τα επιθηλία του πνεύμονα και άλλους αναπνευστικούς ιστούς. Aντιθέτως, οι ορότυποι 40 και 41 έχουν φυσική θυγατρική σχέση προς τη γαστροεντερική οδό. Οι ορότυποι που περιγράφονται παραπάνω, διαφέρουν σε τουλάχιστον πρωτεΐνες καψιδίου (με βάση πεντόνιο, εξόνιο), πρωτεΐνες υπεύθυνες για σύνδεση κυττάρου (πρωτεΐνη ίνας) και πρωτεΐνες που ενέχονται σε αντιγραφή αδενοϊού. Αυτή η διαφορά στο τροπισμό και στην πρωτεΐνη καψιδίου μεταξύ οροτύπων έχει οδηγήσει σε πολλές ερευνητικές προσπάθειες που στοχεύουν την επανακατεύθυνση του τροπισμού αδενοϊού με τροποποίηση των πρωτεϊνών καψιδίου.
CY20111101074T 1999-05-17 2011-11-07 Ανασυνδυασμενος αδενοϊος οροτυπου ad11 CY1112008T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201545 1999-05-17
EP07106036A EP1818408B1 (en) 1999-05-17 2000-05-16 Recombinant Adenovirus of the Ad11 serotype

Publications (1)

Publication Number Publication Date
CY1112008T1 true CY1112008T1 (el) 2015-11-04

Family

ID=8240209

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20071100996T CY1106762T1 (el) 1999-05-17 2007-07-25 Ανασυνδυασμενος ανθρωπινος αδενοϊος οροτυπου 35
CY20111100030T CY1111494T1 (el) 1999-05-17 2011-01-10 ΑΝΑΣΥΝΔΥΑΣΜΕΝΟΣ ΑΔΕΝΟΪΟΣ ΤΟΥ Αd26 ΟΡΟΤΥΠΟΥ
CY20111101075T CY1112189T1 (el) 1999-05-17 2011-11-07 Ανασυνδυασμενος αδενοϊος βασιζομενος στον οροτυπο 48 (ad48)
CY20111101074T CY1112008T1 (el) 1999-05-17 2011-11-07 Ανασυνδυασμενος αδενοϊος οροτυπου ad11

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20071100996T CY1106762T1 (el) 1999-05-17 2007-07-25 Ανασυνδυασμενος ανθρωπινος αδενοϊος οροτυπου 35
CY20111100030T CY1111494T1 (el) 1999-05-17 2011-01-10 ΑΝΑΣΥΝΔΥΑΣΜΕΝΟΣ ΑΔΕΝΟΪΟΣ ΤΟΥ Αd26 ΟΡΟΤΥΠΟΥ
CY20111101075T CY1112189T1 (el) 1999-05-17 2011-11-07 Ανασυνδυασμενος αδενοϊος βασιζομενος στον οροτυπο 48 (ad48)

Country Status (14)

Country Link
EP (6) EP1818408B1 (el)
JP (2) JP4843145B2 (el)
KR (1) KR100741247B1 (el)
AT (6) ATE519855T1 (el)
AU (1) AU777041B2 (el)
CA (1) CA2372655C (el)
CY (4) CY1106762T1 (el)
DE (4) DE60035229T2 (el)
DK (6) DK1818408T3 (el)
ES (5) ES2231103T5 (el)
IL (3) IL146479A0 (el)
NZ (1) NZ515582A (el)
PT (5) PT1550722E (el)
WO (1) WO2000070071A1 (el)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731767B2 (en) 1995-06-15 2001-04-05 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (en) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
JP2003534805A (ja) 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン 変化した親和性を有する改変ウシアデノウイルス
EP1322774A2 (en) * 2000-09-20 2003-07-02 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for dendritic cells
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1195440A1 (en) * 2000-10-06 2002-04-10 Introgene B.V. Gene delivery vectors for stem cells
WO2002029073A2 (en) * 2000-10-06 2002-04-11 Crucell Holland B.V. Gene delivery vectors for stem cells
DE60234496D1 (de) * 2001-01-04 2010-01-07 Goeran Wadell Virusvektor zur gentherapie
IL152423A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel vector constructs
CA2474763A1 (en) * 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
MXPA04008891A (es) * 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
CN100374574C (zh) * 2002-04-25 2008-03-12 克鲁塞尔荷兰公司 稳定的腺病毒载体及其增殖方法
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
SG156535A1 (en) 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
AU2004260044B2 (en) * 2003-07-18 2009-04-23 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
ATE435906T1 (de) 2004-02-23 2009-07-15 Crucell Holland Bv Verfahren zur reinigung von viren
JP2007532656A (ja) * 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
KR101169109B1 (ko) 2004-05-26 2012-07-26 싸이오서스 테라퓨틱스 엘티디. 암 치료에 사용하기 위한 키메릭 아데노바이러스
EA010433B1 (ru) * 2004-10-13 2008-08-29 Круселл Холланд Б.В. Усовершенствованные аденовирусные векторы и их применение
CN101090974B (zh) 2004-11-16 2011-05-11 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
US7888102B2 (en) 2005-07-22 2011-02-15 Crucell Holland B.V. Cell line for producing coronaviruses
WO2007104792A2 (en) * 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
SG178254A1 (en) 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
US20120315696A1 (en) * 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
CA2786835C (en) * 2010-02-15 2021-08-31 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013139916A1 (en) 2012-03-22 2013-09-26 Crucell Holland B.V. Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US9476061B2 (en) 2012-05-24 2016-10-25 Janssen Vaccines & Prevention B.V. Adenoviral vectors for transduction of vascular tissue
EP2872172B1 (en) 2012-07-10 2018-11-14 Transgene SA Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
JP2015536147A (ja) 2012-11-16 2015-12-21 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 組換えアデノウイルスおよびその使用
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
KR20190062617A (ko) 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
IL250743B (en) 2014-09-03 2022-08-01 Bavarian Nordic As Methods and compositions for inducing protective immunity against filovirus infection
AU2015320574B2 (en) 2014-09-26 2018-12-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against Human Immunodeficiency Virus infection
HUE040440T2 (hu) 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
PL3283634T3 (pl) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
RS60105B1 (sr) 2015-04-30 2020-05-29 Psioxus Therapeutics Ltd Onkološki adenovirus kodiran proteinom b7
BR112017027448A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv vacina contra rsv
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
AU2016309743B2 (en) 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
HUE045993T2 (hu) 2015-12-15 2020-01-28 Janssen Vaccines & Prevention Bv Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások
CN108697746A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的病毒
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
SG11201807913XA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
EA201892735A1 (ru) 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
US10925956B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
EP3681533A1 (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
BR112020007884A2 (pt) 2017-11-20 2020-11-03 Janssen Pharmaceuticals, Inc. método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
EP3723771A4 (en) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. RECOMBINANT ADENOVIRUS AND THEIR USES
MA51312A (fr) 2017-12-19 2020-10-28 Bavarian Nordic As Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
EP3810277A1 (en) 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
BR112021022087A2 (pt) 2019-05-15 2021-12-28 Janssen Vaccines & Prevention Bv Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus
WO2020229579A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
US20210222133A1 (en) 2019-11-18 2021-07-22 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
CN111337042B (zh) * 2020-03-13 2021-11-02 湖北大学 一种车辆路径规划方法及系统
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4178613A1 (en) 2020-07-08 2023-05-17 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
US20220194999A1 (en) 2020-12-23 2022-06-23 Janssen Biotech, Inc. Neoantigen Peptide Mimics
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
AU731767B2 (en) 1995-06-15 2001-04-05 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
EP1159438B1 (en) * 1999-03-04 2008-07-30 Crucell Holland B.V. Use of adenoviral vector for synovial cell transduction
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections

Also Published As

Publication number Publication date
ATE519855T1 (de) 2011-08-15
NZ515582A (en) 2003-11-28
EP1816205B1 (en) 2011-08-10
PT1550722E (pt) 2007-09-25
DK1054064T4 (da) 2010-05-03
ATE445018T1 (de) 2009-10-15
JP4843145B2 (ja) 2011-12-21
ES2231103T3 (es) 2005-05-16
AU4954700A (en) 2000-12-05
EP1818408A1 (en) 2007-08-15
IL146479A (en) 2011-12-29
ES2372824T3 (es) 2012-01-26
JP2002543846A (ja) 2002-12-24
ES2354578T3 (es) 2011-03-16
ES2231103T5 (es) 2010-04-15
DE60035229T2 (de) 2008-02-21
EP1550722B1 (en) 2007-06-13
PT1054064E (pt) 2005-02-28
JP2011224014A (ja) 2011-11-10
DK1550722T3 (da) 2007-10-08
IL214413A0 (en) 2011-09-27
DE60035229D1 (de) 2007-07-26
CA2372655C (en) 2011-11-15
ATE485382T1 (de) 2010-11-15
PT1818408E (pt) 2011-11-15
EP1681353B1 (en) 2009-10-07
DE60043126D1 (de) 2009-11-19
EP1816204B1 (en) 2010-10-20
DE60045138D1 (de) 2010-12-02
EP1054064B1 (en) 2004-10-06
DK1816204T3 (da) 2011-01-24
EP1681353A1 (en) 2006-07-19
DE60014489D1 (de) 2004-11-11
PT1816204E (pt) 2011-01-24
ES2372823T3 (es) 2012-01-26
AU777041B2 (en) 2004-09-30
EP1054064A1 (en) 2000-11-22
EP1550722A1 (en) 2005-07-06
ES2289426T3 (es) 2008-02-01
DK1818408T3 (da) 2011-10-17
DK1816205T3 (da) 2011-11-21
CY1106762T1 (el) 2012-05-23
KR20020028879A (ko) 2002-04-17
DK1054064T3 (da) 2005-01-10
CA2372655A1 (en) 2000-11-23
CY1111494T1 (el) 2015-08-05
CY1112189T1 (el) 2015-12-09
DE60014489T2 (de) 2005-11-24
DE60014489T3 (de) 2010-08-12
EP1816205A1 (en) 2007-08-08
EP1818408B1 (en) 2011-08-10
EP1816204A1 (en) 2007-08-08
EP1054064B2 (en) 2009-12-16
DK1681353T3 (da) 2010-01-04
IL146479A0 (en) 2002-07-25
ATE364707T1 (de) 2007-07-15
ATE278792T1 (de) 2004-10-15
IL214413A (en) 2014-04-30
KR100741247B1 (ko) 2007-07-19
JP5335037B2 (ja) 2013-11-06
ATE519854T1 (de) 2011-08-15
WO2000070071A1 (en) 2000-11-23
PT1816205E (pt) 2011-11-15

Similar Documents

Publication Publication Date Title
CY1112008T1 (el) Ανασυνδυασμενος αδενοϊος οροτυπου ad11
FI951138A (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
LT2003107A (en) Pulmonary adminstration of chemically modified insulin
EE05538B1 (et) Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine
JP2004537952A5 (el)
NO20050008L (no) Neisserial vaksinesammensetninger omfattende en kombinasjon av antigener
ATE237694T1 (de) Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE69702911T2 (de) Oxydierte oligosaccharide
DK1762145T3 (da) Teksturerede cellulose- og lignocellulosematerialer og sammensætninger og kompositmaterialer fremstillet ud fra disse
DK2301953T3 (da) Bindingsmolekyler til human faktor VIII og faktor VIII-lignende proteiner
EP1213624A3 (en) Sheet inverter system
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
WO2004035616A3 (de) Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
NO20020329D0 (no) Antitumor antistoffer, proteiner og anvendelser derav
BRPI0100837B8 (pt) sequência de dna que codifica a proteína externa de membrana antigênica e específica de salmonella typhi
WO2007081938A3 (en) Mannheimia haemolytica chimeric outer membrane protein plpe and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
AU2002314705A1 (en) Adenovirus serotype 30 (ad30) fiber protein and uses thereof
Hamilton No red faces, they hope.
Stroup GET WRAPPING.
SE0102998D0 (sv) Anordning och sätt för att forma en matta